Issue of Equity

Bioventix plc ("Bioventix" or the "Company") Issue of Equity Bioventix plc (AIM: BVXP) announces that it has today applied for 6,729ordinary shares of 5 pence each (the "Option Shares") to be admitted to tradingon AIM ("Admission"). It is expected that Admission will occur and thatdealings will commence in the Option Shares on 14 November 2014. The Option Shares are being issued pursuant to the exercise of options by aformer employee of the Company. The Option Shares will rank pari passu with theexisting ordinary shares of 5 pence each in the capital of the Company("Ordinary Shares"). The total number of Ordinary Shares in issue following Admission will be5,050,931 and the Company holds no shares in treasury. Therefore the totalnumber of Ordinary Shares with voting rights in the Company is 5,050,931. The above figure of 5,050,931 may be used by shareholders as the denominatorfor the calculations by which they will determine if they are required tonotify their interest in, or a change to their interest in, Bioventix under theFCA's Disclosure and Transparency Rules. For further information please contact: Bioventix plc Chief Executive Officer Tel: 01252 728 001Peter Harrison finnCap Ltd Corporate Finance Tel: 020 7220 0500Geoff Nash/Simon Hicks Corporate BrokingStephen Norcross About Bioventix plc: Bioventix (www.bioventix.com) specialises in the development and commercialsupply of high-affinity monoclonal antibodies with a primary focus on theirapplication in clinical diagnostics, such as in automated immunoassays used inblood testing. The antibodies created at Bioventix are generated in sheep andare of particular benefit where the target is present at low concentration andwhere conventional monoclonal or polyclonal antibodies have failed to produce asuitable reagent. Bioventix currently offers a portfolio of antibodies tocustomers for both commercial use and R&D purposes, for the diagnosis ormonitoring of a broad range of conditions, including heart disease, cancer,fertility, thyroid function and drug abuse. Bioventix currently suppliesantibody products and services to the majority of multinational clinicaldiagnostics companies. Bioventix is based in Farnham, UK and its shares aretraded on AIM under the symbol BVXP.